$0.11
21.02%
Nasdaq, Fri, Dec 27 2024
ISIN
BSP733981026
Symbol
NYMX

Nymox Pharmaceutical Corp Stock price

$0.11
-0.04 26.33% 1M
-0.09 46.10% 6M
-0.48 81.27% YTD
-0.64 85.27% 1Y
-0.94 89.48% 3Y
-2.31 95.43% 5Y
-0.28 72.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 21.02%
ISIN
BSP733981026
Symbol
NYMX
Sector

Key metrics

Market capitalization $10.34m
Enterprise Value $11.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.35m
Free Cash Flow (TTM) Free Cash Flow $-4.02m
Cash position $70.00k
EPS (TTM) EPS $-0.10
Short interest 4.65%
Show more

Is Nymox Pharmaceutical Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Nymox Pharmaceutical Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Nymox Pharmaceutical Corp:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Nymox Pharmaceutical Corp:

Buy
100%

Financial data from Nymox Pharmaceutical Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
0% 0%
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses 4.35 4.35
34% 34%
-
- Research and Development Expense 3.98 3.98
-
-
-8.34 -8.34
26% 26%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -8.35 -8.35
26% 26%
-
Net Profit -8.84 -8.84
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nymox Pharmaceutical Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Head office Bahamas
CEO Paul Averback
Founded 1995
Website www.nymox.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today